Prognostic factors related to postoperative survival in the newly classified clinical T4 lung cancer.

OBJECTIVES T4 lung cancer has become a more heterogeneous group since the 8th edition of tumour, node, metastasis classification. The aim of this study was to identify predictive factors related to post-surgical survival in patients with clinical T4 non-small-cell lung cancer (NSCLC), based on the 8th edition of the classification. METHODS We retrospectively reviewed consecutive patients with clinical T4 NSCLC who underwent resection between January 2006 and December 2016, to identify factors associated with overall survival. RESULTS Ninety-three patients were identified. The criteria for clinical T4 disease included tumours larger than 7 cm (n = 54), great vessels or left atrial invasion (n = 22), mediastinal invasion (n = 11), vertebral invasion (n = 3), tracheal or carina invasion (n = 3), diaphragm invasion (n = 1) and ipsilateral different lobe pulmonary metastasis (n = 2). The postoperative nodal status was 0, 1, 2 and 3 in 59, 18, 15 and 1 patient, respectively. R0 resection was achieved in 80 patients, and the 30-day mortality was 0%. The median follow-up time was 37.6 months, and the 5-year overall survival rate was 56.3%. The multivariable analysis revealed that nodal status and R-status were significant prognostic factors for postoperative survival [hazard ratio (HR) 2.62, 95% confidence interval (CI) 1.20-5.72, P = 0.016 and HR 3.29, 95% CI 1.45-7.44, P = 0.004]. CONCLUSIONS Surgery provided encouraging survival outcomes for clinical T4 NSCLC based on the 8th edition of classification. The nodal status and R-status were significant prognostic factors for postoperative survival.

[1]  Daniel P Steinfort,et al.  Preoperative Staging by EBUS in cN0/N1 Lung Cancer , 2019, Journal of bronchology & interventional pulmonology.

[2]  A. Sakurada,et al.  Chest wall/parietal pleural invasions worsen prognosis in T4 non-small cell lung cancer patients after resection , 2019, General Thoracic and Cardiovascular Surgery.

[3]  Ping Yang,et al.  T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0–1M0 non-small-cell lung cancer† , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  R. Pirker,et al.  Adjuvant Therapy in Patients With Completely Resected Non–small‐cell Lung Cancer: Current Status and Perspectives , 2019, Clinical lung cancer.

[5]  V. Torri,et al.  Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint , 2018, British Journal of Cancer.

[6]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[7]  Iaslc Staging,et al.  The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer , 2017 .

[8]  C. Dooms,et al.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  E. Miyaoka,et al.  Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  P. Granone,et al.  Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. , 2012, The Annals of thoracic surgery.

[11]  J. Soh,et al.  Induction Chemoradiotherapy Followed by Surgical Resection for Clinical T3 or T4 Locally Advanced Non–Small Cell Lung Cancer , 2012, Annals of Surgical Oncology.

[12]  I. Yoshino,et al.  Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors (>7 cm). , 2010, Interactive cardiovascular and thoracic surgery.

[13]  A. Chambers,et al.  Does surgery have a role in T4N0 and T4N1 lung cancer? , 2010, Interactive cardiovascular and thoracic surgery.

[14]  Jian-Hua Fu,et al.  Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. , 2009, The Annals of thoracic surgery.

[15]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .

[16]  C. Ludwig,et al.  Chest wall resection for lung cancer: indications and techniques. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[17]  P. Dartevelle,et al.  Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. , 2008, The Annals of thoracic surgery.

[18]  H. Kato,et al.  Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.